Researchers at the University of California, Irvine (UC Irvine), have uncovered a surprising molecular connection that fundamentally changes the way scientists understand how brain inflammation develops in Alzheimer’s disease.
The study, published in the Proceedings of the National Academy of Sciences, was led by assistant researcher Ruiming Zhao and Dr. Steve Goldstein, vice chancellor for health affairs at UC Irvine. Their team discovered that amyloid precursor proteins (APP) — widely known as the source of amyloid-beta peptides that form plaques in Alzheimer’s disease — form a functional complex with voltage-gated proton channels (Hv1) in microglia, the brain’s immune cells.
Revising the Structure of a Long-Studied Channel
This discovery overturns decades of assumptions about the composition of Hv1 receptor channels. According to the researchers, the structural assembly between APP and Hv1 channels changes the way these channels operate, altering both their electrical properties and pharmacological behavior.
While Hv1 channels exist in various tissues throughout the body, this study focused specifically on the brain, where they influence neuroinflammatory and neurodegenerative processes associated with Alzheimer’s disease.
Key Insights Into Brain Inflammation Mechanisms
The research revealed that when APP or its C99 transmembrane fragments bind to Hv1 channels, they significantly enhance proton currents and promote the release of inflammatory mediators from human microglia derived from induced pluripotent stem cells. In contrast, when APP expression was suppressed, both channel activity and inflammatory molecule production dropped dramatically.
These findings suggest that the interaction between APP and Hv1 channels plays a direct role in controlling inflammatory responses within the brain, offering new insight into how neuroinflammation arises during Alzheimer’s progression.
Linking Genetic Mutations to Early-Onset Alzheimer’s
The UC Irvine team also discovered that two known mutations in the amyloid precursor protein — both associated with early-onset Alzheimer’s disease — further increased Hv1 channel activity beyond normal levels. This hyperactivity may help explain the heightened inflammatory responses observed in patients carrying these mutations.
Such evidence bridges the gap between genetic predispositions and the physiological mechanisms that drive early neurodegeneration, marking a crucial step toward targeted therapeutic strategies.
Expert Perspectives on the Discovery
Senior author Dr. Steve Goldstein emphasized the significance of the finding:
“Hv1 has long been recognized as a regulator of inflammation in immune cells, but discovering that APP — a central protein in Alzheimer’s pathology — directly modifies its behavior was completely unexpected. This finding is exciting because it begins to clarify why Hv1 channels behave differently across tissues in health and disease, information that is essential for developing effective treatments.”
Collaborative Efforts and Institutional Support
This study was supported by the National Institutes of Health (NIH) and the Cure Alzheimer’s Fund. It represents a multidisciplinary collaboration between the Zhao-Goldstein Laboratory and the Blurton-Jones Lab at UC Irvine’s Department of Neurobiology & Behavior, the Institute for Memory Impairments and Neurological Disorders (UCI MIND), and the Sue & Bill Gross Stem Cell Research Center.
Co-authors of the study include Punyanuch Sophanpanichkul, Jean Paul Chadarevian, Yiwen Ding, Mathew Blurton-Jones, Hui Dai, Maha Nayak, and Hayk Davtyan.
Their collective work provides a new framework for understanding the molecular mechanisms that contribute to brain inflammation in Alzheimer’s disease and paves the way for future therapeutic research focused on modulating APP-Hv1 interactions.
Implications for Future Research and Treatment
By identifying this unexpected molecular partnership, the UC Irvine team has provided a new avenue for exploring how inflammatory processes can be controlled in neurodegenerative diseases. The discovery not only advances fundamental neuroscience but also offers potential strategies for developing targeted drugs aimed at stabilizing Hv1 channel behavior or disrupting harmful APP interactions.
Ultimately, this research deepens scientific understanding of how Alzheimer’s disease develops at the cellular level and reinforces the importance of continued investigation into the molecular foundations of neuroinflammation.
Related topics
